Our Partners

CIMTEC has many strong partners in the health technology, commercialization, medical imaging and medical device communities. Partnerships allow us to provide our customers access to a greater pool of expertise, knowledge, and funding opportunities to help their medical imaging innovations succeed.

The Networks of Centres of Excellence (NCE) was established by the Government of Canada in 1989 to mobilize Canada’s best research, development and entrepreneurial expertise focused on specific issues and strategic areas. It was created to strengthen Canada’s global economic competitiveness by making new discoveries and transforming them into products, services and processes that improve the lives of Canadians. NCE programs meet Canada’s need to focus a critical mass of research resources on social and economic challenges, commercialize and apply more of its homegrown research breakthroughs, increase private sector R&D and train highly-qualified people.

CIMTEC is partly funded through the NCE’s Centres of Excellence for Commercialization and Research (CECR) program, which was created in 2007 to bridge the challenging gap between innovation and commercialization. CIMTEC facilitates and enables the commercialization of world-leading medical imaging and digital pathology technology leading to the improved understanding, diagnosis and treatment of human disease.

The Ontario Institute for Cancer Research (OICR) is an innovative cancer research and development institute dedicated to prevention, early detection, diagnosis and treatment of cancer. The Institute is an independent, not-for-profit corporation launched by the Government of Ontario in 2005. OICR's research supports more than 1,700 investigators, clinician scientists, research staff and trainees located at its headquarters and in research institutes and academic settings across the Province of Ontario. OICR has key research efforts underway in small molecules, biologics, stem cells, imaging, genomics, informatics and bio-computing, from early stage research to Phase II clinical trials.

In 2012, CIMTEC was awarded $4 million over four years to conduct work as part of OICR’s Imaging Translation Program. OICR funds also enable CIMTEC to support researchers, start-ups and small and medium-sized enterprises (SMEs) to translate groundbreaking developments in medical imaging and digital pathology into new clinical tools for cancer diagnosis and treatment.

Western University has annual research funding in excess of $220 million, and an international reputation for success. It ranks as one of Canada’s top research-intensive universities with global scale clusters of research excellence, including biomedical imaging. It is home to Schulich School of Medicine & Dentistry and Robarts Research Institute.

Western is one of CIMTEC’s host institutions providing physical infrastructure and administrative support, as well as access to lab and workshop facilities. 

Sunnybrook Health Sciences Centre is the largest single-site hospital in Canada and has four strategic areas of focus: heart and stroke; cancer; trauma, emergency and critical care; and women and babies. It is a fully affiliated teaching hospital of the University of Toronto. Sunnybrook Research Institute has more than 270 scientists and clinician-scientists who  conduct over $100 million of research each year, and have a track record in commercializing their discoveries and innovations. Their work is relevant to several clinical foci, including cancer, heart disease, and disorders of the brain and musculoskeletal system.

Sunnybrook Health Sciences Centre is one of CIMTEC’s host institutions. Our Toronto office is located at the Bayview campus. CIMTEC has access to SRI’s comprehensive imaging facilities, which include a device development laboratory and its cGMP and pre-clinical research facility, all part of SRI’s Centre for Research in Image-Guided Therapeutics.

WORLDiscoveries® is the Business Development arm of the extensive research network in London, Ontario. It acts as a bridge between local invention and global industry.

Born out of a partnership between Western University, Robarts Research Institute and Lawson Health Research Institute, WORLDiscoveries® draws upon a mix of industry connections, sector-specific market knowledge and business development expertise, to help researchers and local inventors commercialize their discoveries through licensing and new company spin-offs.

CIMTEC works closely with WORLDiscoveries® providing subject matter expertise in medical imaging and digital pathology to help bring its research network’s medical imaging innovations to the marketplace.

MaRS Innovation (MI) is a not-for-profit organization located in Toronto. It enjoys the support of the Federal and Ontario Governments and its 16 member institutions, which include some of Ontario's leading universities, teaching hospitals and research institutes, as well as the MaRS Discovery District, as part of Canada's national strategy to close the nation’s translational research gap and improve Canada’s economic security and productivity.

MI is the official commercialization agent for intellectual property created by researchers within its 16 members, most of whom are also based in Toronto. Technologies disclosed to MI's portfolio span therapeutics, medical devices and diagnostic imaging, information and communications technologies and advanced manufacturing and clean technologies.

CIMTEC works with MaRS Innovation to help commercialize medical imaging technologies emerging from its member institutions.

MEDTEQ is a consortium for research and innovation in medical technologies and is located in Montreal, Quebec. Its primary goal is to accelerate the development of new medical technologies through the complementary skills of industry participants, academic and institutional partners as well as university teaching hospitals. MEDTEQ has more than 70 members in the medical technology sector.

MEDTEQ's vision is "Innovation for health".

MEDTEQ's objectives are to:

  • accelerate the integration of new technologies and care pathways within the health system in response to the priorities of healthcare providers;
  • develop knowledge and leading edge expertise in technology and the management of medical systems; and
  • train highly-qualified resources and facilitate knowledge transfer.

 MEDTEQ est un consortium de recherche et d’innovation en technologies médicales qui est situé à Montréal, Québec. Il a pour mission d’accélérer le développement de technologies innovantes en réunissant les compétences complémentaires de partenaires industriels et institutionnels autour de celles des hôpitaux universitaires. MEDTEQ regroupe plus de 70 membres du domaine des technologies médicales.

Sa vision : l’innovation pour la santé.

Ses objectifs:

  • accélérer l’intégration de nouvelles technologies et de nouveaux modes d’intervention dans le système de santé en considérant les priorités des établissements de santé;
  • développer des connaissances et des expertises de pointe dans les technologies et dans la gestion des systèmes médicaux; et
  • former du personnel hautement qualifié et faciliter le transfert de connaissances.

The MedDev (Medical Device) Commercialization Centre (MDCC) is a not-for-profit corporation, and is part of the Centres of Excellence for Commercialization and Research (CECR) program. It is a collaborative network of medical device stakeholders focused on the development and commercialization of viable, safe, reliable, effective and needed medical devices for success in the global clinical market.

The MDCC initiative was devised through the consensus of more than 600 stakeholders from across Canada to fill an important strategic gap in the Canadian medical devices ecosystem. The centre links medical device innovators (universities, colleges, research institutes, hospitals, corporations, individuals, industry and others) with users (investors, industry, hospitals and patients).

MDCC has partnered with CIMTEC to provide financial support to help bring select Canadian medical imaging innovations to the global market.

The Ontario Brain Institute (OBI) is a provincially‐funded, not‐for‐profit research centre seeking to maximize the impact of neuroscience and establish Ontario as a world-leader in brain research, commercialization, and care. Convergent partnerships are created between researchers, clinicians, industry, patients, and their advocates to foster discovery and deliver innovative products and services that improve the lives of those living with brain disorders.

For the Ontario Brain Institute, commercialization is a critical step in translating research ideas into better patient care, and partnerships are at the root of translation.
OBI is working with industry to help catalyze the translation of brain research ideas into products that can improve the care of those living with brain disorders. The Institute is focused on accelerating the commercialization of brain-related technologies through the development of collaborative partnerships between the private sector and not-for-profit institutions.

Both OBI and CIMTEC share a common goal of creating a successful ecosystem of medical technology companies offering effective new diagnoses and treatments. They will continue to work together to commercialize Canadian and Ontario innovations by focusing on accelerating prototype development and testing for startups.  

Lawson Health Research Institute, located in London, Ontario, is one of Canada’s largest and most respected hospital-based research institutes. As the research arm of London Health Sciences Centre and St. Joseph’s Health Care London, and working in partnership with Western University, Lawson is committed to furthering scientific knowledge to advance health care around the world.

Its state-of-the-art, nuclear imaging program includes Canada’s first and only PET/MRI scanner, a PET/CT scanner, and the Cyclotron & PET Radiochemistry Facility, a modern GMP facility operating under a Health Canada Drug Establishment License. The facility includes a GE PETtrace 880 cyclotron with F-18, C-11, N-13 and high-powered solid target capabilities, class 100 shielded hot cells, and automated synthesis units for F-18and C-11 radiopharmaceuticals. The Lawson Imaging program is focused on translating research discoveries through commercialization and to clinical use.

Lawson has one of Canada’s most respected imaging programs and employs approximately 60 imaging scientists. Its imaging research laboratories are in close proximity to patient care, which ensures that clinical need is the foundation for technology development. The Institute’s scientists interact closely with radiologists and nuclear medicine clinicians to help solve clinical imaging challenges for improved patient care. The Lawson Imaging program is focused on translating research discoveries through commercialization and to clinical use.

CIMTEC has access to Lawson’s clinical trials centre to provide clinical testing services involving imaging modalities to CIMTEC’s customers.